260 related articles for article (PubMed ID: 26350273)
1. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
Kapil RP; Cipriano A; Wen W; Yu Lynch S; He E; Colucci SV; Harris SC
Clin Ther; 2016 Feb; 38(2):302-14. PubMed ID: 26749219
[TBL] [Abstract][Full Text] [Related]
5. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology.
Darwish M; Bond M; Yang R; Tracewell W; Robertson P
Clin Drug Investig; 2015 Oct; 35(10):645-52. PubMed ID: 26369654
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
Darwish M; Bond M; Tracewell W; Robertson P; Yang R
Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
[TBL] [Abstract][Full Text] [Related]
9. Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2017 Jul; 18(7):1278-1291. PubMed ID: 27651514
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study.
Chen R; Shen K; Hu P
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):110-4. PubMed ID: 26754303
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain.
Robinson CY; Rubino CM; Farr SJ
J Opioid Manag; 2015; 11(5):405-15. PubMed ID: 26535968
[TBL] [Abstract][Full Text] [Related]
12. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
Bond M; Rabinovich-Guilatt L; Selim S; Darwish M; Tracewell W; Robertson P; Yang R; Malamut R; Colucci P; Ducharme MP; Spiegelstein O
Clin Drug Investig; 2017 Dec; 37(12):1153-1163. PubMed ID: 28948482
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
14. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
16. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
17. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Adewole T; Qin P; Maletic V; Schwabe S; Nasser A
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1365-1374. PubMed ID: 33943033
[TBL] [Abstract][Full Text] [Related]
18. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects.
Chen R; Shen K; Hu P
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):853-860. PubMed ID: 28933337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
